Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial

Key Takeaways

• Edwards Lifesciences’ RESILIA tissue demonstrates sustained performance over 10 years in the COMMENCE aortic trial
• Long-term durability data supports earlier treatment of valve disease patients with improved outcomes
• Results presented at American Association for Thoracic Surgery Annual Meeting strengthen Edwards’ cardiovascular portfolio

---

Edwards Lifesciences Reports Decade-Long Success for RESILIA Tissue

Edwards Lifesciences Corporation (NYSE: EW) announced compelling 10-year results from its COMMENCE aortic trial, demonstrating the exceptional long-term durability of its proprietary RESILIA tissue technology. The landmark data were presented at the 106th American Association for Thoracic Surgery Annual Meeting in Chicago.

Clinical Significance and Patient Impact

The decade-long follow-up data reinforces RESILIA tissue’s sustained performance in aortic valve replacement procedures, providing crucial evidence for clinicians treating valve disease. As medical evidence increasingly supports earlier intervention in valve disease progression, these durability results could influence treatment timing decisions and patient outcomes.

The COMMENCE trial represents one of the most comprehensive long-term studies evaluating tissue valve performance, offering insights into how Edwards’ proprietary tissue technology maintains structural integrity and functionality over extended periods.

Market Implications for Cardiovascular Devices

These positive 10-year results strengthen Edwards Lifesciences’ position in the competitive cardiovascular device market, particularly in surgical aortic valve replacement. The durability data may influence physician preference and hospital procurement decisions, as long-term performance becomes increasingly important in value-based healthcare environments.

The timing of this announcement coincides with growing emphasis on treating valve disease patients earlier in disease progression, potentially expanding the addressable patient population for Edwards’ RESILIA technology.

Looking Forward

With robust 10-year data now available, Edwards Lifesciences is well-positioned to support regulatory submissions and clinical adoption globally. The company continues to advance its cardiovascular portfolio, with RESILIA tissue representing a key component of its surgical valve offerings.

---

Frequently Asked Questions

What does this mean for patients needing aortic valve replacement?

The 10-year durability data suggests patients receiving RESILIA tissue valves can expect sustained performance over the long term, potentially reducing the need for repeat procedures and improving quality of life.

When will these results impact clinical practice?

RESILIA tissue is already commercially available, and these 10-year results provide additional evidence for physicians to consider when selecting valve replacement options for their patients.

How does RESILIA tissue compare to other valve replacement options?

The 10-year COMMENCE trial data positions RESILIA tissue favorably among tissue valve options, though direct comparative studies would be needed to make definitive comparisons with competing technologies.

Related coverage

• Obesity rates in America by year: what the data shows
• Breast Cancer Statistics Worldwide: What the Data Shows
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial